Estrone sulfate sodium

Name: Estrone sulfate sodium
Brand: MedChemExpress
SKU: HY-113293B
Rating: 5.0 (3 reviews)

Cat. No.: HY-113293B Purity: 99.84%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research.

For research use only. We do not sell to patients.

Estrone sulfate sodium Chemical Structure

CAS No. : 438-67-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Estrone sulfate sodium:

Estrone sulfate-d₄ sodium In-stock
Estrone sulfate potassium In-stock
Estrone sulfate-d₅ sodium Get quote
Estrone sulfate Get quote
Estrone sulfate sodium (Standard) Get quote

3 Publications Citing Use of MCE Estrone sulfate sodium

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Estrone sulfate (1.0 μM; 1-64 min) sodium is taken up at a low rate by dispersed normal breast parenchymal cells, resulting in a cells/medium concentration ratio of 0.20-0.33 when incubated at 37°C^[2].
Estrone sulfate (1.0 nM-100 μM) sodium is converted to estrone by dispersed normal breast parenchymal cells with a mean half-time of 628 min per 10⁶ cells (intact cells) or 246 min per 10⁶ cells (homogenized cells)^[2].
Estrone sulfate sodium is not produced via conversion of estrone by dispersed normal breast parenchymal cells under conditions where MCF-7 breast cancer cells exhibit sulfotransferase activity^[2].
Estrone sulfate sodium stimulates colony formation in dispersed nitrosomethylurea mammary cells and is converted to estrone and estradiol by these cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Estrone sulfate (30-3000 pmol/hr; 400-1300 pmol/hr; s.c.; continuous infusion; 14 days) sodium exerts dose-related stimulatory effects on nitrosomethylurea-induced hormone-responsive mammary tumor growth in castrate rats, with significant conversion to estrone and estradiol^[3].
Estrone sulfate (75 mg/kg; p.o; daily; for 5 days) sodium reduces glucose-6-phosphatase activity and protein levels, and lowers blood glucose in ob/ob mice^[4].
Estrone sulfate sodium modulates glucose-6-phosphatase kinetic parameters in control mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (female, castrated, nitrosomethylurea-induced mammary tumor model)^[3]
Dosage:	30 pmol/hr; 300 pmol/hr; 3000 pmol/hr; 400 pmol/hr; 1300 pmol/hr
Administration:	s.c.; continuous infusion; 14 days
Result:	Did not significantly alter castration-induced tumor regression at 30 pmol/hr; partially blunted castration-induced tumor regression at 300 pmol/hr; stimulated tumor growth at 3000 pmol/hr; Observed significantly different tumor growth slopes for 300 and 3000 pmol/hr doses; Detected 14%, 10%, and 13% conversion to estradiol, and 24%, 22%, and 28% conversion to estrone on days 7, 10, and 14, respectively, at 400 pmol/hr; Recorded similar conversion rates at 1300 pmol/hr; Measured serum estradiol levels of 17 pg/ml (400 pmol/hr), 56 pg/ml (1300 pmol/hr), 6.8 ± 1.2 pg/ml (300 pmol/hr, day 14), and 48 ± 10.2 pg/ml (3000 pmol/hr, day 14).

Molecular Weight

372.41

Formula

C₁₈H₂₁NaO₅S

CAS No.

438-67-5

Appearance

Solid

Color

White to off-white

SMILES

C[C@]1([C@](CC2)([H])[C@]3([H])CCC4=C(C=CC(OS(=O)(O[Na])=O)=C4)[C@@]3([H])CC1)C2=O

Structure Classification

Steroids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (67.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6852 mL	13.4261 mL	26.8521 mL
5 mM	0.5370 mL	2.6852 mL	5.3704 mL
10 mM	0.2685 mL	1.3426 mL	2.6852 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.84%

Select Batch:

Data Sheet (281 KB) SDS (418 KB)

COA (252 KB) HNMR (275 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Yang Z, et al. Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. ACS Omega. 2025;10(44):52562-52575. Published 2025 Oct 29. [Content Brief]

[2]. Chatterton RT Jr, et al. Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol. 2003;86(2):159-166. [Content Brief]

[3]. Santner SJ, et al. Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinoma in vivo in the rat. Int J Cancer. 1990;46(1):73-78. [Content Brief]

[4]. Borthwick EB, et al. The antihyperglycemic effect of estrone sulfate in genetically obese-diabetic (ob/ob) mice is associated with reduced hepatic glucose-6-phosphatase. Horm Metab Res. 2001 Dec;33(12):721-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6852 mL	13.4261 mL	26.8521 mL	67.1303 mL
	5 mM	0.5370 mL	2.6852 mL	5.3704 mL	13.4261 mL
	10 mM	0.2685 mL	1.3426 mL	2.6852 mL	6.7130 mL
	15 mM	0.1790 mL	0.8951 mL	1.7901 mL	4.4754 mL
	20 mM	0.1343 mL	0.6713 mL	1.3426 mL	3.3565 mL
	25 mM	0.1074 mL	0.5370 mL	1.0741 mL	2.6852 mL
	30 mM	0.0895 mL	0.4475 mL	0.8951 mL	2.2377 mL
	40 mM	0.0671 mL	0.3357 mL	0.6713 mL	1.6783 mL
	50 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3426 mL
	60 mM	0.0448 mL	0.2238 mL	0.4475 mL	1.1188 mL